The problem is not the review. It is everything before the review.
Pharma assets take, on average, 21 to 56 days to clear MLR and reach deployment. That number gets quoted as if the reviewers are the bottleneck. They are not. The bottleneck is what arrives on the reviewer's desk: inconsistent claim language, missing references, off-brand colours, accessibility gaps nobody checked, version conflicts that force a reject-and-resubmit before any medical judgement happens.
That is the layer AI should be removing. Not the strategy, not the medical review, not the creative direction. The administrative friction that sits underneath all of it and makes skilled people spend hours on work no human should be doing.
At Promedia we have spent the last year building small, purpose-built tools against exactly that friction. The result inside the agency: output doubled, team size did not. The result for clients: assets that are more compliant, more accessible, and closer to right the first time.
How to scale pharma content production without hiring more staff
The instinct, when a pharma brand team is drowning in deliverables, is to add people. More designers, more copywriters, more project managers. It works for a while. Then the coordination cost eats the capacity gain, and you are back where you started with a bigger payroll.
The alternative is to look at where senior people spend their time and ask which parts of that work are repetitive, rule-based, and verifiable. Those are the parts a small tool can handle. Not a general-purpose AI assistant. A boring, specific tool that does one thing reliably.
Four examples from our own build list:
- A WCAG plugin inside Figma that scans a full component library against WCAG 2.2 in minutes.
- A brand compliance checker that runs on every asset before it ships, measuring colours, tokens, typography, and spacing against the design system.
- A claim library with AI-assisted assembly, where approved statements carry source, audience, status, and expiry metadata.
- A design system audit tool that maps token structure, flags inconsistencies, and generates an improvement roadmap before anyone touches a file.
None of these replace the designer, the strategist, or the medical reviewer. They remove the layer underneath.
How does a WCAG plugin in Figma speed up accessibility audits
Manual WCAG audits on a pharma design system typically take a designer two weeks. The plugin runs the same scan in minutes and returns a prioritised fix list. The Promedia WCAG plugin checks every component in the Figma library against WCAG 2.2 and flags contrast failures, missing alt-text structures, focus-state problems, and touch target issues in a single report.
The timing matters. Directive (EU) 2019/882, the European Accessibility Act, has been in force across all 27 EU Member States since 28 June 2025. It mandates WCAG 2.1 and 2.2-aligned accessibility for consumer-facing digital products, patient portals and mobile apps included. Pharma companies are fully in scope. Penalties reach €100,000 or 4% of annual turnover.
Accessibility that used to be a nice-to-have is now a compliance obligation with teeth. Running the audit manually once a year will not keep up with the pace of digital asset production. Running it automatically on every component commit will.
How to automate brand compliance checks for pharma assets
Brand compliance on emails and e-details is often checked manually, by a project manager eyeballing a PDF, or not checked at all. Off-brand assets reach the market. The brand team finds out from a sales rep three weeks later.
An AI brand compliance checker compares any asset against the design system and generates a report on logo usage, fonts, colours, and brand rules. Our working proof of concept does exactly that. It does not approve or reject. It surfaces the gaps so a human can make the call before the asset ships, not after.
The same logic underpins the design system audit tool. Before you can enforce consistency, you need to know where the inconsistencies live. The audit maps token structure, flags conflicts, and produces the roadmap. Everything else, the compliance checker, the WCAG plugin, the modular claim library, builds on that foundation.
How can AI reduce MLR review rounds in pharma
Industry estimates put AI-optimised MLR workflow improvements at around a 57% reduction in review cycle time and a 55% cut in time spent in review meetings. McKinsey estimates content creation cost savings of 30 to 50% when AI is applied properly across the pharma content lifecycle.
Those numbers are not achieved by having AI write the content. They are achieved by applying AI upstream, before submission, so that content arrives with complete reference packages, consistent claim language, pre-marked sources, and no version conflicts. Reviewers then make substantive medical and regulatory decisions instead of sending work back for administrative corrections.
A modular claim library is the practical mechanism. Approved statements, tagged with source and audience and expiry, assembled into new assets by validated component rather than written from scratch. The MLR team reviews what actually changed, not the whole asset again. Review rounds shrink. Approvals land faster. The brand team gets its launch window back.